id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-282750-d9sb7o63	Benhadou, F.	Improvement of SARS‐CoV2 symptoms following Guselkumab injection in a psoriatic patient	2020-05-07		.txt	text/plain	550	28	44	We read with great interest the publication of Messina et al (1) reporting the first case of SARS‐CoV2 infection in a young patient of 32‐year‐old suffering from psoriasis and psoriatic arthritis treated by Guselkumab, a monoclonal antibody that targets specifically the p19 subunit of Interleukin (IL)‐23(2).The patient contracted the SARS‐CoV2 infection after a dinner with some friends but fortunately she developed very discrete symptoms including only mild fever and rhinorrhea. arthritis treated by Guselkumab, a monoclonal antibody that targets specifically the p19 subunit of Interleukin (IL)-23 2 .The patient contracted the SARS-CoV2 infection after a dinner with some friends but fortunately she developed very discrete symptoms including only mild fever and rhinorrhea. These findings support the potential role of IL-23p19 inhibitors to counteract the « cytokine storm » triggered by the SARS-CoV2 and which is potentially implicated in the severity of the symptoms 3 .	./cache/cord-282750-d9sb7o63.txt	./txt/cord-282750-d9sb7o63.txt